Analysis of HLA-G gene polymorphism and protein expression in invasive breast ductal carcinoma

Human Immunology

Volumn 75, Issue 7, 2014, Pages 667-672

  Ramos, Caroline Steglich ^a   Gonçalves, Andréia Souza ^b   Marinho, Larissa Cardoso ^a   Gomes Avelino, Melissa Ameloti ^b   Saddi, Vera Aparecida ^a,e   Lopes, Aryanne Cristina ^a   Simões, Renata Toscano ^c   Wastowski, Isabela Jubé ^d  

^a PONTIFÍCIA UNIVERSIDADE CATÓLICA DE GOIÁS   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^c Postgraduate Program of Santa Casa   (Brazil)

^d UNIVERSIDADE ESTADUAL DE GOIÁS   (Brazil)

^e Laboratory of Oncogenetics and Radiobiology Association of Cancer Combat in Goiás   (Brazil)

Author keywords

Breast cancer; HLA G; Polymorphism; Tumor escape

Indexed keywords

HLA G ANTIGEN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENE INSERTION; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; ALLELE; BREAST TUMOR; CANCER STAGING; CASE CONTROL STUDY; GENE EXPRESSION; GENE FREQUENCY; GENETICS; IMMUNOLOGY; INDEL MUTATION; LYMPH NODE; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL;

ALLELES; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; GENE FREQUENCY; HLA-G ANTIGENS; HUMANS; INDEL MUTATION; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84902263449     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.04.005     Document Type: Article

References (30)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
3. Voduc K.D., Cheang M.C., Tyldesley S., Gelmon K., Nielsen T.O., Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010, 28:1684-1691.
4. Favier B., LeMaoult J., Rouas-Freiss N., Moreau P., Menier C., Carosella E.D. Research on HLA-G: an update. Tissue Antigens 2007, 69:207-211.
5. Shiroishi M., Tsumoto K., Amano K., Shirakihara Y., Colonna M., Braud V.M., et al. Human inhibitory receptors Ig-like transcript 2 [ILT2] and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci USA 2003, 100:8856-8861.
6. Torres M.I., Le Discorde M., Lorite P., Ríos A., Gassull M.A., Gil A., et al. Expression of HLA-G in inflammatory bowel disease provides a potential way to distinguish between ulcerative colitis and Crohn's disease. Int Immunol 2004, 16:579-583.
7. Lajoie J., Hargrove J., Zijenah L.S., Humphrey J.H., Ward B.J., Roger M. Genetic variants in nonclassical major histocompatibility complex class I human leukocyte antigen [HLA]-E and HLA-G molecules are associated with susceptibility to heterosexual acquisition of HIV-1. J Infect Dis 2006, 193:298-301.
8. Rouas-Freiss N., Moreau P., Ferrone S., Carosella E.D. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?. Cancer Res 2005, 65:10139-10144.
9. Martelli-Palomino G., Pancotto J.A., Muniz Y.C., Mendes-Junior C.T., Castelli E.C., Massaro J.D., et al. Polymorphic sites at the 3' untranslated region of the HLA-G gene are associated with differential HLA-G soluble levels in the Brazilian and French population. PLOS ONE 2013, 8(10):71-74. 10.1371/journal.pone.0071742.
10. Edge S.B., Compton C.C. The american joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17:1471-1474.
11. Hviid T.V., Hylenius S., Hoegh A.M., Kruse C., Christiansen O.B. HLA-G polymorphisms in couples with recurrent spontaneous abortions. Tissue Antigens 2002, 60:122-132.
12. Caras I., Grigorescu A., Stavaru C., Radu D.L., Mogos I., Szegli G., et al. Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother 2004, 53:1146-1152.
13. Molling J.W., Kölgen W., Vliet H.J., Boomsma M.F., Kruizenga H., Smorenburg C.H., et al. Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer 2005, 116:87-93.
14. Pinzon-Charry A., Ho C.S., Maxwell T., McGuckin M.A., Schmidt C., Furnival C., et al. Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer. Br J Cancer 2007, 97:1251-1259.
15. Wolf A.M., Wolf D., Steurer M., Gastl G., Gunsilius E., Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 2003, 9:606-612.
16. Diaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., Montero A.J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009, 58:49-59.
17. Crane C.A., Panner A., Murray J.C., Wilson S.P., Xu H., Chen L., et al. PI[3] kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene 2009, 28:306-312.
18. He X., Dong D.D., Yie S.M., Yang H., Cao M., Ye S.R., et al. HLA-G expression in human breast cancer: implications for diagnosis and prognosis, and effect on allocytotoxic lymphocyte response after hormone treatment in vitro. Ann Surg Oncol 2010, 17:1459-1469.
19. Sayed D., Badr G., Maximous D., Mikhail N.N., Abu-Tarboush F., Alhazza I.M. HLA-G and its relation to proliferation index in detection and monitoring breast cancer patients. Tissue Antigens 2010, 75:40-47.
20. Elliott R.L., Jiang X.P., Phillips J.T., Barnett B.G., Head J.F. Human leukocyte antigen G expression in breast cancer: role in immunosuppression. Cancer Biother Radiopharm 2011, 26:153-157.
21. Lefebvre S., Antoine M., Uzan S., McMaster M., Dausset J., Carosella E.D., et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 2002, 196:266-274.
22. Caumartin J., Favier B., Daouya M., Guillard C., Moreau P., Carosella E.D., et al. Trogocytosis-based generation of suppressive NK cells. EMBO J 2007, 26:1423-1433.
23. Zidi I., Ben Amor N. HLA-G as predisposing for metastasis. Med Hypotheses 2011, 77:134-139.
24. Kawada K., Taketo M.M. Significance and mechanism of lymph node metastasis in cancer progression. Cancer Res 2011, 71:1214-1218.
25. Cai M.B., Han H.Q., Bei J.X., Liu C.C., Lei J.J., Cui Q., et al. Expression of human leukocyte antigen G is associated with prognosis in nasopharyngeal carcinoma. Int J Biol Sci 2012, 8:891-900.
26. Wang Y., Ye Z., Meng X.Q., Zheng S.S. Expression of HLA-G in patients with hepatocellular carcinoma Hepatobiliary. Pancreat Dis Int 2011, 10:158-163.
27. Yie S.M., Yang H., Ye S.R., Li K., Dong D.D., Lin X.M. Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol 2007, 128:1002-1009.
28. Dardano A., Rizzo R., Polini A., Stignani M., Tognini S., Pasqualetti G., et al. Soluble human leukocyte antigen-g and its insertion/deletion polymorphism in papillary thyroid carcinoma: novel potential biomarkers of disease?. J Clin Endocrinol Metab 2012, 97:4080-4086.
29. Shankarkumar U., Shankarkumar A., Chedda Z., Ghosh K. Role of 14-bp deletion/insertion polymorphism in exon 8 of the HLA-G gene in recurrent spontaneous abortion patients. J Hum Reprod Sci 2011, 4:143-146.
30. Boiocchi C., Bozzini S., Zorzetto M., Pelissero G., Cuccia M., Falcone C. Association between two polymorphisms in the HLA-G gene and angiographic coronary artery disease. Mol Med Rep 2012, 5:1141-1145.